Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis Source: Eur Respir J 2001; 17: 64-70 Year: 2001
The bronchoprotective effects of levocetirizine on adenosine monophosphate challenge in patients with atopic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004
The adenosine A2A -Receptor is not involved in adenosine induced bronchoconstriction in asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Protection by formoterol and salmeterol on bronchoconstriction provoked by methacholine and AMP in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 307s Year: 2002
Association between atopic status and airway reactivity to methacholine and adenosine monophosphate Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
An improved bronchial provocation test with dry powder adenosine instead of nebulised adenosine monophosphate (AMP) Source: International Congress 2017 – Monitoring asthma control Year: 2017
Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction Source: Eur Respir J 2004; 23: 559-564 Year: 2004
Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Protective effect on AMP airway responsiveness after a single dose of fluticasone Source: Eur Respir J 2004; 24 : 711-712 Year: 2004
Protective effect of budesonide/formoterol in a model of repeated exposure to inhaled adenosine 5‘-monophosphate (AMP) in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 353s Year: 2007
Effects of salbutamol on gas exchange abnormalities and sputum neutrophilia induced by adenosine 5‘-monophosphate (AMP) in mild asthma Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response Source: Eur Respir J 2003; 22: Suppl. 45, 204s Year: 2003
Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 502s Year: 2002
Effect of budesonide on AMP and methacholine airway responsiveness and sputum cellularity: a time-course study Source: Eur Respir J 2001; 18: Suppl. 33, 163s Year: 2001
Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Rapid protective effect of inhaled fluticasone on airway hyperresponsiveness to AMP in patients with fixed airway obstruction due to asthma but not COPD Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
Differences in responsiveness of airways to AMP and methacholine in asthma and COPD Source: Eur Respir J 2001; 18: Suppl. 33, 93s Year: 2001